These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 10446883)

  • 1. Do infliximab and methotrexate act synergistically in the treatment of rheumatoid arthritis? Comment on the article by Maini et al.
    Rezaian MM
    Arthritis Rheum; 1999 Aug; 42(8):1779-81. PubMed ID: 10446883
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic effect of methotrexate and infliximab on activated lymphocyte apoptosis.
    van den Brande JM; Peppelenbosch MP; Hommes DW
    Inflamm Bowel Dis; 2007 Jan; 13(1):118-9. PubMed ID: 17206648
    [No Abstract]   [Full Text] [Related]  

  • 3. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
    Matsuno H; Yoshida K; Ochiai A; Okamoto M
    J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
    Lipsky PE; van der Heijde DM; St Clair EW; Furst DE; Breedveld FC; Kalden JR; Smolen JS; Weisman M; Emery P; Feldmann M; Harriman GR; Maini RN;
    N Engl J Med; 2000 Nov; 343(22):1594-602. PubMed ID: 11096166
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
    Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotic syndrome associated with anti-tumor necrosis factor alpha therapy in a patient with rheumatoid arthritis: comment on the article by Charles et al.
    den Broeder AA; Assmann KJ; van Riel PL; Wetzels JF
    Arthritis Rheum; 2002 Jun; 46(6):1691-3; author reply 1693. PubMed ID: 12115204
    [No Abstract]   [Full Text] [Related]  

  • 7. Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.
    Harriman G; Harper LK; Schaible TF
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I61-4. PubMed ID: 10577975
    [No Abstract]   [Full Text] [Related]  

  • 8. Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
    Maini RN; Taylor PC; Paleolog E; Charles P; Ballara S; Brennan FM; Feldmann M
    Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I56-60. PubMed ID: 10577974
    [No Abstract]   [Full Text] [Related]  

  • 9. Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.
    Francis S; Block MJ
    Arthritis Rheum; 2010 Sep; 62(9):2826; author reply 2826-8. PubMed ID: 20556822
    [No Abstract]   [Full Text] [Related]  

  • 10. Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis.
    Keating GM; Perry CM
    BioDrugs; 2002; 16(2):111-48. PubMed ID: 11985485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rheumatoid arthritis and tumor necrosis factor alpha.
    Abe T; Takeuchi T
    Autoimmunity; 2001; 34(4):291-303. PubMed ID: 11905855
    [No Abstract]   [Full Text] [Related]  

  • 12. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
    Antoni C; Kalden JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study.
    Smolen JS; Han C; Bala M; Maini RN; Kalden JR; van der Heijde D; Breedveld FC; Furst DE; Lipsky PE;
    Arthritis Rheum; 2005 Apr; 52(4):1020-30. PubMed ID: 15818697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ten years of infliximab: insights from clinical trials in rheumatoid arthritis.
    Smolen JS
    Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S5-9. PubMed ID: 19843471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infliximab: a review of its use in the management of rheumatoid arthritis.
    Markham A; Lamb HM
    Drugs; 2000 Jun; 59(6):1341-59. PubMed ID: 10882166
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al.
    Grinblat B; Scheinberg M
    Arthritis Rheum; 2005 Apr; 52(4):1333-4; author reply 1334. PubMed ID: 15818679
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy with biologic agents in rheumatoid arthritis: perils and promise.
    Kremer JM
    Arthritis Rheum; 1998 Sep; 41(9):1548-51. PubMed ID: 9751086
    [No Abstract]   [Full Text] [Related]  

  • 19. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.
    Lyseng-Williamson KA; Foster RH
    Pharmacoeconomics; 2004; 22(2):107-32. PubMed ID: 14731052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12.
    van Oosterhout M; Levarht EW; Sont JK; Huizinga TW; Toes RE; van Laar JM
    Ann Rheum Dis; 2005 Apr; 64(4):537-43. PubMed ID: 15769913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.